Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to tackle lymphoma without chemo

NCT ID NCT05783596

Ongoing Disease control Sponsor: Reid Merryman, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a combination of two immunotherapy drugs, glofitamab and obinutuzumab, as the first treatment for people with follicular lymphoma or marginal zone lymphoma. The study includes 47 participants who have not had prior therapy for their lymphoma. The goal is to see how well the drugs work together to shrink or eliminate cancer, and to check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Glofitamab and obinutuzumab (immunotherapy drugs given by IV)
What this could lead to
If successful, this combination could become a new first-line treatment option for people with follicular or marginal zone lymphoma, potentially improving response rates without needing chemotherapy.
What could go wrong
This is an early phase 2 study with only 47 participants, so results may not apply to everyone. Side effects from immunotherapy can be serious, and the treatment may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma indolent B-cell non-Hodgkin lymphoma Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOLLICULAR LYMPHOMA INDOLENT NON-HODGKIN LYMPHOMA MARGINAL ZONE LYMPHOMA

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Columbia University Irving Medical Center

    New York, New York, 10032, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Mount Sinai Medical Center

    New York, New York, 10128, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.